Strides Pharma Science · NSE: STAR · BSE: 532531

Q1 FY20 results · Apr–Jun 2019

Strides Pharma Science reported revenue from operations of ₹685.80 crore (up 3.4% from Q1 FY19) and net profit of ₹2.91 crore for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY20	Q1 FY19	YoY	Q4 FY19	QoQ
Revenue from operations	685.80	663.46	+3.4%	839.70	−18.3%
Other income	10.25	10.64	−3.7%	14.59	−29.7%
Total income	696.05	674.10	+3.3%	854.29	−18.5%
Profit before share of associates & JVs and tax	46.29	(0.51)	Turned profit	76.01	−39.1%
Share of profit/(loss) of associates & JVs	(17.81)	(7.91)		(21.15)
Net profit for the period	2.91	(4.16)	Turned profit	44.70	−93.5%
Attributable to shareholders of the company	3.70	(5.91)	Turned profit	47.51	−92.2%
EPS, basic (₹)	0.41	(0.66)	Turned profit	5.31	−92.3%
Net margin (%)	0.4	-0.6		5.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY20	Q1 FY19	YoY	Q4 FY19	QoQ
Revenue from operations	442.53	349.77	+26.5%	434.56	+1.8%
Other income	23.08	15.77	+46.4%	56.41	−59.1%
Total income	465.61	365.54	+27.4%	490.97	−5.2%
Profit before tax	30.34	11.92	+154.5%	94.90	−68.0%
Net profit for the period	24.68	10.54	+134.2%	98.82	−75.0%
EPS, basic (₹)	2.76	1.18	+133.9%	11.04	−75.0%
Net margin (%)	5.6	3.0		22.7

Consolidated

Filed with BSE: 30 Jul 2019, 10:56 IST
Board meeting: 29 Jul 2019
Period: 01 Apr 2019 to 30 Jun 2019
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 30 Jul 2019, 10:56 IST
Board meeting: 29 Jul 2019
Period: 01 Apr 2019 to 30 Jun 2019
Review status: Unaudited
Source: XBRL filing on BSE